Protara Announces Proposed Public Offering

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of $75 million in common stock or pre-funded warrants to fund clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering consists of $75 million in shares of common stock or pre-funded warrants, with the possibility of underwriters purchasing additional shares within 30 days [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - Protara intends to use the net proceeds from the offering to fund the clinical development of TARA-002 and other clinical programs [1]. - Additional uses for the proceeds may include working capital and general corporate purposes [1]. Group 3: Regulatory Information - The shares and warrants will be issued under a shelf registration statement declared effective by the SEC on November 14, 2023 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3].